An investigation was announced for investors in NASDAQ:AMGN shares over potential securities laws violations by Amgen, Inc..
Investors who purchased shares of Amgen, Inc. (NASDAQ:AMGN), have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 – 1554.
The investigation by a law firm focuses on whether a series of statements by Amgen, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On May 21, 2017, Amgen, Inc. announced data from data from active-comparator study of EVENITY™ (Romosozumab) in postmenopausal women with osteoporosis. Amgen, Inc disclosed that its osteoporosis medicine Evenity raised concerns about heart safety that will lead to a delay in securing approval in the United States. According to data disclosed by Amgen, Inc., a higher percentage of patients who took the drug suffered serious cardiovascular side effects after a year, compared to those who took an older approved medicine. Shares of Amgen, Inc. (NASDAQ:AMGN) declined on May 23, 2017 to $152.16 per share.
Those who purchased NASDAQ:AMGN shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego
The post NASDAQ:AMGN Investor News: Investigation of Amgen, Inc. announced appeared first on Ground Report.
This post first appeared on 6 Surprising Benefits Of Custom Graphic Design To Build Your Brand, please read the originial post: here